News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
588,894 Results
Type
Article (42451)
Company Profile (349)
Press Release (546094)
Section
Business (167678)
Career Advice (2429)
Deals (30310)
Drug Delivery (102)
Drug Development (78592)
Employer Resources (148)
FDA (14343)
Job Trends (12967)
News (295885)
Policy (28492)
Tag
Academia (2655)
Alliances (42759)
Alzheimer's disease (1314)
Approvals (14283)
Artificial intelligence (147)
Bankruptcy (316)
Best Places to Work (10633)
Biotechnology (279)
Breast cancer (186)
Cancer (1370)
Cardiovascular disease (119)
Career advice (2040)
Cell therapy (295)
Clinical research (62614)
Collaboration (474)
Compensation (195)
COVID-19 (2521)
C-suite (119)
Data (1388)
Diabetes (169)
Diagnostics (5646)
Earnings (60360)
Employer resources (136)
Events (87966)
Executive appointments (402)
FDA (14991)
Funding (429)
Gene therapy (212)
GLP-1 (630)
Government (4182)
Healthcare (17183)
Infectious disease (2613)
Inflammatory bowel disease (121)
Interviews (519)
IPO (14111)
Job creations (2753)
Job search strategy (1678)
Layoffs (412)
Legal (6019)
Lung cancer (208)
Manufacturing (192)
Medical device (11007)
Medtech (11011)
Mergers & acquisitions (16348)
Metabolic disorders (468)
Neuroscience (1659)
NextGen Class of 2024 (5955)
Non-profit (4112)
Northern California (1581)
Obesity (261)
Opinion (210)
Parkinson's disease (100)
Patents (118)
People (53421)
Phase I (19628)
Phase II (27665)
Phase III (20604)
Pipeline (512)
Postmarket research (2389)
Preclinical (8304)
Radiopharmaceuticals (246)
Rare diseases (275)
Real estate (4485)
Regulatory (19722)
Research institute (2267)
Resumes & cover letters (359)
Southern California (1413)
Startups (3170)
United States (14035)
Vaccines (540)
Weight loss (197)
Date
Today (5)
Last 7 days (567)
Last 30 days (2256)
Last 365 days (33594)
2024 (33428)
2023 (37498)
2022 (48412)
2021 (52024)
2020 (50011)
2019 (42546)
2018 (32072)
2017 (29660)
2016 (28193)
2015 (32972)
2014 (25387)
2013 (20574)
2012 (21784)
2011 (22690)
2010 (20430)
Location
Africa (737)
Arizona (137)
Asia (35841)
Australia (7129)
California (3610)
Canada (1382)
China (288)
Colorado (158)
Connecticut (156)
Europe (80324)
Florida (488)
Georgia (118)
Illinois (346)
Indiana (201)
Maryland (598)
Massachusetts (2730)
Michigan (164)
Minnesota (250)
New Jersey (1040)
New York (1022)
North Carolina (704)
Northern California (1581)
Ohio (130)
Pennsylvania (823)
South America (1012)
Southern California (1413)
Texas (497)
Utah (108)
Washington State (372)
588,894 Results for "aquestive therapeutics formerly known as monosolrx".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Aquestive Therapeutics, Inc. announced that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host investor meetings on July 9, 2024.
June 27, 2024
·
2 min read
Business
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Aquestive Therapeutics, Inc. today announced the appointment of Abigail Jenkins to the Company’s Board of Directors, effective April 1, 2024.
April 1, 2024
·
6 min read
Business
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
Aquestive Therapeutics, Inc. today announced it has strengthened its leadership team with three executive appointments ahead of the anticipated launch of Anaphylm™.
June 3, 2024
·
8 min read
Deals
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
Aquestive Therapeutics, Inc. today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share.
March 25, 2024
·
2 min read
Press Releases
Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 4, 2024
·
35 min read
Press Releases
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film
December 2, 2024
·
9 min read
Pharm Country
Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics, Inc. today released positive topline pharmacokinetic (PK) data from the temperature / pH study of its product candidate Anaphylm™ (epinephrine) Sublingual Film.
June 25, 2024
·
10 min read
Press Releases
Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five
December 19, 2024
·
11 min read
Pharm Country
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference 2024
Aquestive Therapeutics, Inc., a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies, announced that the management team will participate in The Citizens JMP Life Sciences Conference on May 13, 2024.
May 9, 2024
·
3 min read
Pharm Country
Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
Aquestive Therapeutics, Inc. today announced that it will report results for the first quarter ended March 31, 2024 and provide an update on recent developments in its business after market close on Tuesday, May 7, 2024.
April 25, 2024
·
3 min read
1 of 58,890
Next
